

1. Sales January to March 2011 and 2010

	2011	2010	% change	
	CHF m	CHF m	In CHF	In local currencies
January – March				
Pharmaceuticals Division	8,712	9,727	-10	-2
United States	3,322	3,647	-9	+2
Western Europe	2,209	2,597	-15	-4
Japan	903	988	-9	-7
International	2,278	2,495	-9	-3
Diagnostics Division	2,408	2,518	-4	+6
Roche Group	11,120	12,245	-9	0

2. Quarterly local sales growth by Division in 2010 and 2011

	Q2 2010	Q3 2010	Q4 2010	Q1 2011
	vs. Q2 2009	vs. Q3 2009	vs. Q4 2009	vs. Q1 2010
Pharmaceuticals Division	-2	-5	-8	-2
United States	-5	-1	-8	+2
Western Europe	-2	-11	-13	-4
Japan	-3	-22	-11	-7
International	+4	+5	-1	-3
Diagnostics Division	+9	+7	+6	+6
Roche Group	0	-3	-5	0

3. Quarterly sales by Division in 2010 and 2011

CHF millions	Q1 2010	Q2 2010	Q3 2010	Q4 2010	Q1 2011
Pharmaceuticals Division	9,727	9,659	9,009	8,663	8,712
United States	3,647	3,725	3,506	3,193	3,322
Western Europe	2,597	2,447	2,251	2,172	2,209
Japan	988	1,073	1,076	1,182	903
International	2,495	2,414	2,176	2,116	2,278
Diagnostics Division	2,518	2,732	2,482	2,683	2,408
Roche Group	12,245	12,391	11,491	11,346	11,120

4. Sales January to March 2011 and 2010 excluding Tamiflu

	2011	2010	% change	
	CHF m	CHF m	In CHF	In local currencies
January – March				
Pharmaceuticals Division	8,460	9,210	-8	+1
United States	3,148	3,477	-9	+2
Western Europe	2,201	2,594	-15	-4
Japan	855	862	-1	+1
International	2,256	2,277	-1	+6
Diagnostics Division	2,408	2,518	-4	+6
Roche Group	10,868	11,728	-7	+2

5. Quarterly local sales growth by Division in 2010 and 2011 excluding Tamiflu

	Q2 2010	Q3 2010	Q4 2010	Q1 2011
	vs. Q2 2009	vs. Q3 2009	vs. Q4 2009	vs. Q1 2010
Pharmaceuticals Division	+3	+4	+4	+1
United States	+2	+4	+2	+2
Western Europe	+2	-1	-2	-4
Japan	+1	+2	+7	+1
International	+6	+12	+13	+6
Diagnostics Division	+9	+7	+6	+6
Roche Group	+4	+5	+4	+2

6. Quarterly sales by Division in 2010 and 2011 excluding Tamiflu

CHF millions	Q1 2010	Q2 2010	Q3 2010	Q4 2010	Q1 2011
Pharmaceuticals Division	9,210	9,466	8,911	8,598	8,460
United States	3,477	3,694	3,504	3,153	3,148
Western Europe	2,594	2,447	2,251	2,173	2,201
Japan	862	1,057	1,030	1,154	855
International	2,277	2,268	2,126	2,118	2,256
Diagnostics Division	2,518	2,732	2,482	2,683	2,408
Roche Group	11,728	12,198	11,393	11,281	10,868

7. Top 20 Pharmaceuticals Division product sales and local growth YTD March 2011 vs. YTD March 2010: US, Western Europe, Japan and International

	Total		United States		Western Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	1,556	7%	713	5%	411	5%	57	9%	375	15%
Avastin	1,417	-6%	648	-14%	393	-8%	143	22%	233	16%
Herceptin	1,386	8%	374	3%	513	1%	64	-3%	435	25%
Lucentis	392	35%	392	35%	-	-	-	-	-	-
Pegasys	346	-15%	65	-28%	87	-2%	25	-2%	169	-16%
Xeloda	342	7%	123	13%	69	-4%	27	2%	123	10%
Tarceva	317	8%	118	10%	101	-2%	20	22%	78	16%
CellCept	280	-14%	54	-27%	83	-24%	14	16%	129	-1%
Tamiflu	252	-47%	174	15%	8	169%	48	-61%	22	-90%
NeoRecormon/Epogin	246	-22%	-	-	87	-30%	85	-15%	74	-17%
Bonviva/Boniva	212	-15%	104	-19%	63	-10%	-	-	45	-9%
Xolair	149	13%	149	13%	-	-	-	-	-	-
Valcyte/Cymevene	145	8%	68	8%	41	1%	-	-	36	18%
Pulmozyme	131	8%	75	11%	27	1%	-	-	29	5%
Actemra/RoActemra	129	111%	27	548%	45	88%	40	35%	17	338%
Activase/TNKase	122	23%	111	24%	-	-	-	-	11	13%
Nutropin	87	8%	85	8%	-	-	-	-	2	-15%
Madopar	75	8%	-	-	24	-2%	5	10%	46	14%
Rocephin	73	-5%	-	-82%	19	32%	13	2%	41	-15%
Mircera	70	30%	-	-	45	11%	-	-	25	86%

8. Top 20 Pharmaceuticals Division quarterly local product sales growth

	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009	Q1 2011 vs. Q1 2010
MabThera/Rituxan	6%	6%	10%	7%
Avastin	10%	7%	2%	-6%
Herceptin	5%	8%	5%	8%
Lucentis	27%	34%	20%	35%
Pegasys	-4%	-8%	9%	-15%
Xeloda	16%	16%	14%	7%
Tarceva	10%	9%	0%	8%
CellCept	-15%	-14%	5%	-14%
Tamiflu	-72%	-90%	-94%	-47%
NeoRecormon/Epogin	-16%	-16%	-18%	-22%
Bonviva/Boniva	0%	2%	-13%	-15%
Xolair	10%	10%	5%	13%
Valcyte/Cymevene	4%	11%	14%	8%
Pulmozyme	0%	2%	5%	8%
Actemra/RoActemra	175%	176%	158%	111%
Activase/TNKase	15%	15%	-3%	23%
Nutropin	-4%	19%	11%	8%
Madopar	10%	11%	7%	8%
Rocephin	-6%	8%	2%	-5%
Mircera	50%	37%	37%	30%

9. Pharmaceuticals Division quarterly local product sales growth United States

	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009	Q1 2011 vs. Q1 2010
MabThera/Rituxan	2%	2%	6%	5%
Avastin	1%	-3%	-10%	-14%
Herceptin	0%	4%	7%	3%
Lucentis	27%	34%	20%	35%
Pegasys	0%	-12%	6%	-28%
Xeloda	26%	8%	10%	13%
Tarceva	10%	13%	-6%	10%
CellCept	-47%	-47%	40%	-27%
Tamiflu	-91%	-97%	-89%	15%
NeoRecormon/Epogin	-	-	-	-
Bonviva/Boniva	-9%	2%	-21%	-19%
Xolair	10%	10%	5%	13%
Valcyte/Cymevene	2%	13%	18%	8%
Pulmozyme	5%	-1%	2%	11%
Actemra/RoActemra	-	-	-	548%
Activase/TNKase	16%	16%	-3%	24%
Nutropin	-4%	20%	11%	8%
Madopar	-	-	-	-
Rocephin	-62%	-	-	-82%
Mircera	-	-	-	-

10. Pharmaceuticals Division quarterly local product sales growth Western Europe

	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009	Q1 2011 vs. Q1 2010
MabThera/Rituxan	7%	5%	5%	5%
Avastin	9%	4%	-3%	-8%
Herceptin	5%	4%	1%	1%
Lucentis	-	-	-	-
Pegasys	-11%	-4%	2%	-2%
Xeloda	6%	1%	7%	-4%
Tarceva	5%	-8%	-5%	-2%
CellCept	-2%	-2%	-7%	-24%
Tamiflu	-	-100%	-	169%
NeoRecormon/Epogin	-25%	-26%	-30%	-30%
Bonviva/Boniva	9%	0%	-2%	-10%
Xolair	-	-	-	-
Valcyte/Cymevene	7%	10%	7%	1%
Pulmozyme	-8%	-1%	1%	1%
Actemra/RoActemra	317%	210%	114%	88%
Activase/TNKase	-	-	-	-
Nutropin	-	-	-	-
Madopar	-1%	-3%	4%	-2%
Rocephin	-1%	0%	-18%	32%
Mircera	28%	18%	20%	11%

11. Pharmaceuticals Division quarterly local product sales growth Japan

	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009	Q1 2011 vs. Q1 2010
MabThera/Rituxan	5%	8%	16%	9%
Avastin	51%	51%	50%	22%
Herceptin	-20%	-15%	-10%	-3%
Lucentis	-	-	-	-
Pegasys	-13%	-4%	5%	-2%
Xeloda	84%	64%	33%	2%
Tarceva	35%	45%	45%	22%
CellCept	15%	12%	25%	16%
Tamiflu	-76%	-88%	-89%	-61%
NeoRecormon/Epogin	-10%	-10%	-11%	-15%
Bonviva/Boniva	-	-	-	-
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Pulmozyme	-	-	-	-
Actemra/RoActemra	62%	60%	74%	35%
Activase/TNKase	-	-	-	-
Nutropin	-	-	-	-
Madopar	1%	2%	5%	10%
Rocephin	2%	-2%	6%	2%
Mircera	-	-	-	-

12. Pharmaceuticals Division quarterly local product sales growth International

	Q2 2010 vs. Q2 2009	Q3 2010 vs. Q3 2009	Q4 2010 vs. Q4 2009	Q1 2011 vs. Q1 2010
MabThera/Rituxan	14%	16%	25%	15%
Avastin	33%	34%	32%	16%
Herceptin	20%	29%	13%	25%
Lucentis	-	-	-	-
Pegasys	-1%	-9%	16%	-16%
Xeloda	2%	28%	21%	10%
Tarceva	11%	26%	10%	16%
CellCept	4%	8%	3%	-1%
Tamiflu	-21%	-70%	-99%	-90%
NeoRecormon/Epogin	-10%	-4%	-7%	-17%
Bonviva/Boniva	11%	6%	-6%	-9%
Xolair	-	-	-	-
Valcyte/Cymevene	6%	8%	13%	18%
Pulmozyme	-3%	18%	22%	5%
Actemra/RoActemra	861%	900%	458%	338%
Activase/TNKase	3%	2%	5%	13%
Nutropin	-7%	-16%	-5%	-15%
Madopar	21%	23%	9%	14%
Rocephin	-9%	16%	18%	-15%
Mircera	160%	138%	94%	86%

13. Top 20 Pharmaceuticals Division quarterly product sales

CHF millions	Q1 2010	Q2 2010	Q3 2010	Q4 2010	Q1 2011
MabThera/Rituxan	1,606	1,695	1,520	1,535	1,556
Avastin	1,666	1,727	1,608	1,460	1,417
Herceptin	1,417	1,389	1,357	1,266	1,386
Lucentis	327	370	384	377	392
Pegasys	441	428	384	392	346
Xeloda	352	380	361	333	342
Tarceva	326	348	331	320	317
CellCept	357	345	299	289	280
Tamiflu	517	193	98	65	252
NeoRecormon/Epogin	339	338	312	296	246
Bonviva/Boniva	277	267	246	223	212
Xolair	148	176	167	150	149
Valcyte/Cymevene	149	147	157	152	145
Pulmozyme	135	129	121	128	131
Actemra/RoActemra	66	89	107	135	129
Activase/TNKase	110	117	119	114	122
Nutropin	91	102	117	95	87
Madopar	75	79	77	77	75
Rocephin	82	83	77	69	73
Mircera	61	63	61	70	70

14. Pharmaceuticals Division quarterly product sales United States

CHF millions	Q1 2010	Q2 2010	Q3 2010	Q4 2010	Q1 2011
MabThera/Rituxan	763	822	729	712	713
Avastin	845	887	802	656	648
Herceptin	408	418	398	367	374
Lucentis	327	370	384	377	392
Pegasys	102	106	92	89	65
Xeloda	123	147	136	124	123
Tarceva	120	138	138	127	118
CellCept	83	76	62	54	54
Tamiflu	170	31	2	40	174
NeoRecormon/Epogin	-	-	-	-	-
Bonviva/Boniva	144	140	132	110	104
Xolair	148	176	167	150	149
Valcyte/Cymevene	70	73	86	74	68
Pulmozyme	75	76	73	76	75
Actemra/RoActemra	5	9	18	26	27
Activase/TNKase	100	105	109	101	111
Nutropin	88	100	114	92	85
Madopar	-	-	-	-	-
Rocephin	2	1	-1	-1	-
Mircera	-	-	-	-	-

15. Pharmaceuticals Division quarterly product sales Western Europe

CHF millions	Q1 2010	Q2 2010	Q3 2010	Q4 2010	Q1 2011
MabThera/Rituxan	442	422	394	381	411
Avastin	484	462	423	393	393
Herceptin	570	527	506	472	513
Lucentis	-	-	-	-	-
Pegasys	99	92	78	83	87
Xeloda	81	78	73	73	69
Tarceva	116	116	98	102	101
CellCept	123	117	108	103	83
Tamiflu	3	0	0	-1	8
NeoRecormon/Epogin	141	125	111	97	87
Bonviva/Boniva	79	76	68	70	63
Xolair	-	-	-	-	-
Valcyte/Cymevene	46	41	41	41	41
Pulmozyme	30	27	26	26	27
Actemra/RoActemra	27	33	37	39	45
Activase/TNKase	-	-	-	-	-
Nutropin	-	-	-	-	-
Madopar	27	27	25	27	24
Rocephin	16	15	13	13	19
Mircera	46	43	43	47	45

16. Pharmaceuticals Division quarterly product sales Japan

CHF millions	Q1 2010	Q2 2010	Q3 2010	Q4 2010	Q1 2011
MabThera/Rituxan	53	69	70	81	57
Avastin	120	156	162	187	143
Herceptin	67	77	74	82	64
Lucentis	-	-	-	-	-
Pegasys	26	31	31	36	25
Xeloda	27	33	33	35	27
Tarceva	17	24	24	29	20
CellCept	12	16	15	18	14
Tamiflu	126	16	46	28	48
NeoRecormon/Epogin	102	123	123	128	85
Bonviva/Boniva	-	-	-	-	-
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Actemra/RoActemra	30	39	43	55	40
Activase/TNKase	-	-	-	-	-
Nutropin	-	-	-	-	-
Madopar	5	6	6	7	5
Rocephin	13	18	16	17	13
Mircera	-	-	-	-	-

17. Pharmaceuticals Division quarterly product sales International

CHF millions	Q1 2010	Q2 2010	Q3 2010	Q4 2010	Q1 2011
MabThera/Rituxan	348	382	327	361	375
Avastin	217	222	221	224	233
Herceptin	372	367	379	345	435
Lucentis	-	-	-	-	-
Pegasys	214	199	183	184	169
Xeloda	121	122	119	101	123
Tarceva	73	70	71	62	78
CellCept	139	136	114	114	129
Tamiflu	218	146	50	-2	22
NeoRecormon/Epogin	96	90	78	71	74
Bonviva/Boniva	54	51	46	43	45
Xolair	-	-	-	-	-
Valcyte/Cymevene	33	33	30	37	36
Pulmozyme	30	26	22	26	29
Actemra/RoActemra	4	8	9	15	17
Activase/TNKase	10	12	10	13	11
Nutropin	3	2	3	3	2
Madopar	43	46	46	43	46
Rocephin	51	49	49	40	41
Mircera	15	20	18	23	25